453 results match your criteria: "Hospital "San Giuseppe Moscati"[Affiliation]"

Background: In the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiority to eculizumab in improving haematological outcomes in adult patients with paroxysmal nocturnal haemoglobinuria and suboptimal response to eculizumab at 16 weeks. The aim of the open-label period was to evaluate the long-term efficacy and safety of pegcetacoplan through to 48 weeks.

Methods: PEGASUS was a phase 3, randomised, open-label, active-comparator controlled trial conducted in 44 centres in Australia, Belgium, Canada, France, Germany, Japan, Russia, South Korea, Spain, the UK, and the USA.

View Article and Find Full Text PDF
Article Synopsis
  • This systematic review investigates the impact of sedation and analgesia on noninvasive ventilation (NIV) for acute respiratory failure (ARF).
  • Despite the growing use of NIV, guidelines on sedation's role are limited, and while some recommend sedation for agitation, definitive recommendations are lacking.
  • The analysis of 16 articles suggests dexmedetomidine is a preferred sedative due to its efficacy and stable cardiorespiratory effects, but further randomized controlled trials are necessary to establish strong evidence-based guidelines.
View Article and Find Full Text PDF

Background: The non-inferiority of dexamethasone (DEX) on day 1, with or without low-dose DEX on days 2 and 3, combined with oral NEPA (netupitant/palonosetron), compared with the guideline-consistent use of DEX was demonstrated in cisplatin. Here, we complete the analysis by assessing the impact of emesis on daily lives of patients receiving DEX-sparing regimens using the Functional Living Index-Emesis (FLIE).

Methods: Chemotherapy-naïve patients undergoing cisplatin (≥70 mg/m), were given NEPA and DEX (12 mg) on day 1 and randomized to receive either 1) no further DEX (DEX1), 2) oral DEX (4 mg daily) on days 2-3 (DEX3), or 3) DEX (4 mg twice daily) on days 2-4 (DEX4; control).

View Article and Find Full Text PDF

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.

Neurology

October 2022

From the CORe (I.R., C.M., T.K.), Department of Medicine, University of Melbourne, Australia; Melbourne MS Centre (I.R., C.M., T.K.), Department of Neurology, Royal Melbourne Hospital, Australia; Rennes, University (E.L.), EHESP, REPERES EA 7449, France; Univ Rennes (E.L.), CHU Rennes, Inserm, CIC 1414 ([Centre d'Investigation Clinique de Rennes]), France; Université de Lyon (R.C.), Université Claude Bernard Lyon 1, France; Hospices Civils de Lyon (R.C.), Service de Neurologie, Sclérose en Plaques, Pathologies de La Myéline et Neuro-inflammation, Bron, France; Observatoire Français de La Sclérose en Plaques (R.C.), Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292, France; Eugène Devic EDMUS Foundation Against Multiple Sclerosis (R.C.), State-approved Foundation, Bron, France; Department of Neurology and Center of Clinical Neuroscience (D.H., E.K.H.), First Faculty of Medicine, Charles University in Prague and General University Hospital, Czech Republic; Nancy University Hospital (M.D.), Department of Neurology, Nancy, France; Université de Lorraine (M.D.), APEMAC, Nancy, France; Department of Medical and Surgical Sciences and Advanced Technologies (F.P.), GF Ingrassia, Catania, Italy; Multiple Sclerosis Center (F.P.), University of Catania, Italy; CHU de Strasbourg (J.D.S.), Department of Neurology and Clinical Investigation Center, CIC 1434, INSERM 1434, Strasbourg, France; Hospital Universitario Virgen Macarena (G.I., S.E.), Sevilla, Spain; CHU Pontchaillou (G.E.), CIC1414 INSERM, Rennes, France; CHUM MS Center and Universite de Montreal (A.P., M.G.), Canada; Dokuz Eylul University (S.O.), Konak/Izmir, Turkey; CISSS Chaudière-Appalache (P.G.), Levis, Canada; CHU Lille (H.Z.), CRCSEP Lille, Univ Lille, U1172, France; CHU de Toulouse (J.C.), Hôpital Pierre-Paul Riquet, Department of Neurology, CRC-SEP, France; Département de Neurologie (E.M.), Hôpital Pitié-Salpêtrière, APHP, Paris; CHU de Dijon (T.M.), Department of Neurology, EA4184, France; Department NEUROFARBA (M.P.A.), University of Florence, Italy; CHU de Montpellier (P.L.), MS Unit, France; University of Montpellier (MUSE) (P.L.), France; Division of Neurology (Raed Alroughani), Department of Medicine, Amiri Hospital, Sharq, Kuwait; Department of Neurology (K.B., O.S.), Box Hill Hospital, Melbourne, Australia; Monash University (K.B., O.S.), Melbourne, Australia; Melbourne MS Centre (K.B.), Royal Melbourne Hospital, Australia; The Alfred Hospital (O.S.), Melbourne, Australia; Medical Faculty (M.T.), 19 Mayis University, Samsun, Turkey; CHU de Nantes (D.A.L.), Service de Neurologie & CIC015 INSERM, France; CRTI-Inserm U1064 (D.A.L.), Nantes, France; CHU de Besançon (E.B.), Service de Neurologie 25 030 Besançon, France; Neuro Rive-Sud (F.G.M.), Quebec, Canada; Neurology (C.L.-F.), UR2CA, Centre Hospitalier Universitaire Pasteur2, Université Nice Côte d'Azur, Nice, France; UOC Neurologia (E.C.), Azienda Sanitaria Unica Regionale Marche-AV3, Macerata, Italy; KTU Medical Faculty Farabi Hospital (C.B.), Trabzon, Turkey; School of Medicine and Public Health (J.L.-S.), University Newcastle, Australia; Department of Neurology (J.L.-S.), John Hunter Hospital, Hunter New England Health, Newcastle, Australia; CHU Clermont-Ferrand (Pierre Clavelou), Department of Neurology; Université Clermont Auvergne, Inserm, Neuro-Dol, Clermont-Ferrand, France; Sorbonne Universités (B.S.), UPMC Paris 06, Brain and Spine Institute, ICM, Hôpital de La Pitié Salpêtrière, Inserm UMR S 1127, CNRS UMR 7225, and Department of Neurology, AP-HP, Saint-Antoine Hospital, Paris, France; CSSS Saint-Jérôme (Julie Prevost), Saint-Jerome, Canada; Neurologic Clinic and Policlinic (L.K.), Departments of Medicine and Clinical Research, University Hospital and University of Basel, Switzerland; Aix Marseille Univ (Jean Pelletier), APHM, Hôpital de La Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, France; Isfahan University of Medical Sciences (V.S.), Iran; Nehme and Therese Tohme Multiple Sclerosis Center (B.I.Y., S.J.K.), American University of Beirut Medical Center, Beirut, Lebanon; Department of Neurology (Oliver Gerlach), Zuyderland Medical Center, Sittard-Geleen, Netherlands; Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino (D.L.A.S.), Italy; Cliniques Universitaires Saint-Luc (V.V.P.), Université Catholique de Louvain, Brussels, Belgium; Fondation Rotschild (Olivier Gout), Department of Neurology, Paris, France; Haydarpasa Numune Training and Research Hospital (R.T.), Istanbul, Turkey; Hôpital de Poissy (O.H.), Department of Neurology, France; Department of Neurology (E.T.), Nimes University Hospital, France; Institut de Génomique Fonctionnelle (E.T.), UMR5203, INSERM 1191, Univ. Montpellier, France; University of Queensland (P.A.M.), Brisbane, Australia; Royal Brisbane and Women's Hospital (P.A.M.), Australia; Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases (A.S.), Istanbul, Turkey; CHU de Rouen (B.B.), Department of Neurology, France; Flinders University (M.S.), Adelaide, Australia; Instituto de Investigación Sanitaria Biodonostia (T.C.-T.), Hospital Universitario Donostia, San Sebastián, Spain; CHU de Reims (S.B.), Department of Neurology, France; Nemocnice Jihlava (Radek Ampapa), Czech Republic; Monash Medical Centre (E.G.B.), Melbourne, Australia; APHP (A.W.), Hôpital Henri Mondor, Department of Neurology, Créteil, France; Austin Health (R.A.M.), Melbourne, Australia; University Hospital Reina Sofia (E.A.-M.), Cordoba, Spain; CHU de La Martinique (Philippe Cabre), Department of Neurology, Fort-de-France, France; Hôpital Sud Francilien (N.H.B.), Department of Neurology, Corbeil Essonnes, France; Department of Neurology (A.V.W., H.B.), The Alfred Hospital, Melbourne, Australia; Central Clinical School (A.V.W., H.B.), Monash University, Melbourne, Australia; Department of Neurology (G.L., L.V.H.), University Hospital Ghent, Belgium; Hospital Germans Trias I Pujol (C.M.R.-T.), Badalona, Spain; CHU La Milétrie (N.M.), Hôpital Jean Bernard, Department of Neurology, Poitiers, France; Liverpool Hospital (S.H.), Sydney, Australia; Hospital de Galdakao-Usansolo (J.L.S.-M.), Spain; Brain and Mind Centre (M.H.B.), Sydney, Australia; CHU Bicêtre (C.L.), Department of Neurology, F-94275 Le Kremlin Bicêtre, France; Westmead Hospital (Steve Vucic), Sydney, Australia; Department of Neurology (Y.S., R.G.), Razi Hospital, Manouba, Tunisia; Department of Neurology (T.C.), Faculty of Medicine, University of Debrecen, Hungary; Hospital Universitari MútuaTerrassa (J.S.), Barcelona, Spain; Groene Hart Ziekenhuis (K.G.), Gouda, Netherlands; Sultan Qaboos University Hospital (A.A.-A.), Al-Khodh, Oman; Universidade Metropolitana de Santos (Y.D.F.), Santos, Brazil; Service de Neurologie (Sandra Vukusic), Sclérose en Plaques, Pathologies de La Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France; Centre des Neurosciences de Lyon (Sandra Vukusic), Observatoire Français de La Sclérose en Plaques, INSERM 1028 et CNRS UMR5292, France; and Université Claude Bernard Lyon 1 (Sandra Vukusic), Faculté de Médecine Lyon Est, France.

Article Synopsis
  • This study evaluates the rate of disease activity return in multiple sclerosis (MS) patients after they stop using disease-modifying therapy, focusing on relapse rates and factors influencing relapse.
  • A large sample of 14,213 patients showed that relapse rates typically increased within 2 months after stopping treatment, with earlier commencement of new therapy reducing these rates significantly.
  • Factors predicting relapse included having a higher relapse rate prior to stopping therapy, being younger, being female, and having a higher Expanded Disability Status Scale (EDSS) score, with subsequent therapy reducing both relapse risk and disability progression.
View Article and Find Full Text PDF

The COVID-19 pandemic has opened several new disease scenarios, yielding novel syndromes that have never been seen before and resurrecting old inflammatory phenomena that are no longer recorded, such as radiation recall (RR) syndromes. Radiation recall syndrome is a limited field inflammatory reaction that occurs in a volume that was irradiated several months or years previously before being induced by a triggering factor. The most frequently reported phenomena are skin reactions; however, other organs could be involved, such as the lungs in radiation recall pneumonitis (RRP).

View Article and Find Full Text PDF

Background: To investigate the effects of the COVID-19 lockdowns on the vasculopathic population. Methods: The Divisions of Vascular Surgery of the southern Italian peninsula joined this multicenter retrospective study. Each received a 13-point questionnaire investigating the hospitalization rate of vascular patients in the first 11 months of the COVID-19 pandemic and in the preceding 11 months.

View Article and Find Full Text PDF

Several myths and misconceptions exist about hormones in women with familial predisposition to cancer, and there are few real-life data on their prescription and uptake. To better understand how they are prescribed and accepted in healthy carriers of a pathogenetic variant, an online survey was uploaded on Google Forms and shared through social media closed groups of patients' associations, aBRCAcadabra and ACTO Campania. A total of 241 questionnaires were collected.

View Article and Find Full Text PDF

Omicron variant of COVID-19 is characterized by exceptional transmissibility and by immune evasion with the ability infect people with naturally acquired or vaccine-induced immunity. However, lung involvement is poorly reported in patients who resulted positive by this new COVID-19 variant. COVID-19 breakthrough infections are defined as COVID-19 infection in fully vaccinated patients.

View Article and Find Full Text PDF

Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls.

Semin Immunol

January 2022

AORN San Giuseppe Moscati Avellino, Italy; Federico II University of Naples, Naples, Italy; French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Saint-Louis Hospital and Université de Paris, Paris, France.

The treatment of paroxysmal nocturnal hemoglobinuria (PNH) was revolutionized by the introduction of the anti-C5 agent eculizumab, which resulted in sustained control of intravascular hemolysis, leading to transfusion avoidance and hemoglobin stabilization in at least half of all patients. Nevertheless, extravascular hemolysis mediated by C3 has emerged as inescapable phenomenon in PNH patients on anti-C5 treatment, frequently limiting its hematological benefit. More than 10 years ago we postulated that therapeutic interception of the complement cascade at the level of C3 should improve the clinical response in PNH.

View Article and Find Full Text PDF

Objective: To investigate in real-life the conversion from chronic migraine (CM) to episodic migraine (EM), specifically to EM with High-Frequency (HFEM: 8-14 monthly migraine days, MMDs), Medium-Frequency (MFEM, 4-7 MMDs), and Low-Frequency EM (LFEM, 0-3 MMDs), and its persistence during 1 year of treatment with galcanezumab.

Methods: Consecutive CM patients treated with galcanezumab completing 1 year of observation were enrolled. We collected data on MMDs, pain intensity (Numeric Rating Scale, NRS score), and monthly acute medication intake (MAMI) from baseline (V1) to the 12-month visit (V12).

View Article and Find Full Text PDF

Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.

Mult Scler

November 2022

Department of Health Sciences, Section of Biostatistics, University of Genova, Genova, Italy/IRCCS Ospedale Policlinico San Martino, Genova, Italy.

Background: Patients with multiple sclerosis (pwMS) treated with anti-CD20 or fingolimod showed a reduced humoral response to SARS-CoV-2 vaccines.

Objective: In this study we aimed to monitor the risk of breakthrough SARS-CoV-2 infection in pwMS on different disease-modifying therapies (DMTs).

Methods: Data on the number of vaccinated patients and the number of patients with a breakthrough infection were retrospectively collected in 27 Italian MS centers.

View Article and Find Full Text PDF

Knowledge of the pathogenic mechanisms of severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2) is certainly a priority for the scientific community. Two main elements are involved in the biology of the most severe forms of coronavirus disease 2019 (COVID-19): the direct cytopathic effect of the virus against the host tissues, and a dysfunction of the immune system, characterized by the exhaustion of T lymphocytes. The exhaustion of T cells in COVID-19 is poorly understand, but some data could suggest a possible role of PD-1/PD-L1 axis.

View Article and Find Full Text PDF

Background: Cognitive dysfunctions are highly prevalent in multiple sclerosis (MS) and negatively impact occupational and social functioning.

Objective: In the present longitudinal study, we aimed at modeling cognitive changes and at assessing whether apathy could be a predictor of cognitive decline in MS.

Methods: We assessed 67 people with MS at two-time points (baseline, T0; 4-year follow-up, T1), by means of several clinical, behavioural, and cognitive measures.

View Article and Find Full Text PDF

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.

BMC Med Res Methodol

May 2022

Arènes - UMR 6051, RSMS (Recherche sur les Services et Management en Santé) - U 1309, Univ Rennes, EHESP, CNRS, Inserm, Rennes, France.

Background: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies.

View Article and Find Full Text PDF
Article Synopsis
  • This study looks at how to predict long-term disability in people with multiple sclerosis (MS) after they show signs of worsening over six months.
  • Researchers checked data from thousands of patients to figure out who is more likely to have lasting problems.
  • They found that things like age, sex, and how MS affects the person can help tell if someone will continue to get worse, which can help doctors in future treatments.
View Article and Find Full Text PDF

Skin exposure is considered a potentially significant but little-studied pathway for PolyChlorinated Biphenyls uptake in terrestrial reptiles. In this study, a native Italian lizard, , was exposed to PCBs-contaminated soil for 120 days. Tissues distribution of PCBs, thyroid hormone levels, and thyroid histo-physiopathology were examined.

View Article and Find Full Text PDF

Background: Even after the publication of the 2017 update of Italian guidelines on treatment of fever in pediatrics, some fundamental questions are still open and new ones emerged during the COVID-19 pandemic.

Objective: To assess the level of consensus among Italian pediatricians on different topics related to treatment of fever in children by using the Delphi technique.

Methods: A Delphi study was undertaken between June and September 2021, when two questionnaires were consecutively sent to a panel of experts to be answered anonymously.

View Article and Find Full Text PDF

Vaccination toward SARS-CoV-2 reduced mortality and 'boosters' are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home "San Giuseppe Moscati" who had received two doses of the BNT162b2 vaccine were enrolled.

View Article and Find Full Text PDF

Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress.

Semin Hematol

January 2022

Severe Aplastic Anemia Working Party (SAAWP) of the European Group for Bone Marrow Transplantation (EBMT), Leiden, Neitherlands; AORN San Giuseppe Moscati Avellino, Italy; Federico II University, Naples.

Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by intravascular hemolysis, thrombosis and bone marrow failure. Prior to the availability of specific therapy, PNH led to the death of around half of affected individuals, mainly through thrombotic complications, with a particular grim prognosis for patients presenting with classic PNH. The anti-C5 monoclonal antibody eculizumab has revolutionized treatment, controlling intravascular hemolysis and thrombosis occurrence, with improved long-term survival.

View Article and Find Full Text PDF

Aortic stenosis is the most common primary valve lesion requiring surgery or, especially for older patients, transcatheter intervention (TAVI). We showcase a successful transfemoral TAVI procedure in a very high-risk patient and an extremely tortuous S-shaped descending aorta, characterized by heavy calcifications and multiple strong resistance points. We demonstrated that transfemoral TAVI using the "buddy stiff guidewire" technique could be a feasible, simple, quick, and easy procedure able to straighten an extremely abdominal aorta tortuosity.

View Article and Find Full Text PDF